238 related articles for article (PubMed ID: 12022707)
1. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
Andersson KE
World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
[TBL] [Abstract][Full Text] [Related]
2. α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists.
Andersson KE
World J Urol; 2002 Apr; 19(6):390-396. PubMed ID: 28386659
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system.
Andersson KE; Gratzke C
Nat Clin Pract Urol; 2007 Jul; 4(7):368-78. PubMed ID: 17615548
[TBL] [Abstract][Full Text] [Related]
4. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
Andersson KE
Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
[TBL] [Abstract][Full Text] [Related]
5. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
8. [The role of alpha1-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench].
Kojima Y; Hayase M; Imura M; Okada S; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Hinyokika Kiyo; 2008 Jun; 54(6):457-62. PubMed ID: 18634446
[TBL] [Abstract][Full Text] [Related]
9. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
10. Future drugs for the treatment of benign prostatic hyperplasia.
Andersson KE; Chapple CR; Höfner K
World J Urol; 2002 Apr; 19(6):436-42. PubMed ID: 12022712
[TBL] [Abstract][Full Text] [Related]
11. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
13. Correlation between expression of α₁-adrenoceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients.
Kojima Y; Sasaki S; Imura M; Kubota Y; Hayashi Y; Kohri K
BJU Int; 2011 Feb; 107(3):438-42. PubMed ID: 20804477
[TBL] [Abstract][Full Text] [Related]
14. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
15. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
Fine SR; Ginsberg P
J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
[TBL] [Abstract][Full Text] [Related]
16. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
[TBL] [Abstract][Full Text] [Related]
17. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
18. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
